Year archive

HighTide Therapeutics, Inc. — 2025 filings

All 34 regulatory filings released by HighTide Therapeutics, Inc. (2511) in 2025, sourced directly from the official regulator.

34 Filings

2025 Period

2025 filings (34)

Filing	Released	Lang
TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE Governance Information	2025-12-24	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025 Share Issue/Capital Change	2025-12-02	English
HIGHTIDE THERAPEUTICS' HTD1801 ACHIEVES GREATER HBA1C REDUCTION AND SUPERIOR CARDIOMETABOLIC MARKER IMPROVEMENT VERSUS DAPAGLIFLOZIN IN PHASE III HEAD-TO-HEAD TRIAL Regulatory Filings	2025-12-02	English
LATE-BREAKING ASN 2025 \| HIGHTIDE THERAPEUTICS PRESENTS EVIDENCE OF RENAL BENEFIT WITH HTD1801 Regulatory Filings	2025-11-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025 Share Issue/Capital Change	2025-11-04	English
HTD1801, A FIRST-IN-CLASS ANTI-INFLAMMATORY METABOLIC MODULATOR, DEMONSTRATES DURABLE 52-WEEK EFFICACY AND SAFETY IN COMPLETION OF TWO PHASE III TRIALS IN TYPE 2 DIABETES MELLITUS Regulatory Filings	2025-10-31	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025 Regulatory Filings	2025-10-02	English
2025 Interim Report Interim / Quarterly Report FY 2025	2025-09-29	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025 Regulatory Filings	2025-09-01	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 Interim / Quarterly Report H2 2025	2025-08-25	English
BUSINESS UPDATE COMMENCING RESEARCH COOPERATION WITH INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES TO EXPLORE THE METABOLIC AND RENAL BENEFITS POTENTIAL OF INNOVATIVE DRUGS Regulatory Filings	2025-08-12	English
NOTICE OF DATE OF BOARD MEETING Regulatory Filings	2025-08-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 Regulatory Filings	2025-08-01	English
Next Day Disclosure Return Share Issue/Capital Change	2025-07-07	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2025-07-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025 Share Issue/Capital Change	2025-07-02	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 27, 2025 Declaration of Voting Results & Voting Rights Announcements	2025-06-27	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2025-06-26	English
2025 SHARE INCENTIVE PLAN Regulatory Filings	2025-06-12	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 27, 2025 Proxy Solicitation & Information Statement	2025-06-05	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-06-05	English
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARE Proxy Solicitation & Information Statement	2025-06-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025 Regulatory Filings	2025-06-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025 Regulatory Filings	2025-05-06	English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2025-04-23	English
2024 ANNUAL REPORT Annual Report	2025-04-23	English
HIGHTIDE THERAPEUTICS ANNOUNCES BERBERINE URSODEOXYCHOLATE (HTD1801) MEETS THE PRIMARY ENDPOINTS IN TWO PHASE 3 CLINICAL TRIALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Regulatory Filings	2025-04-15	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025 Regulatory Filings	2025-04-02	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 Earnings Release FY 2024	2025-03-28	English
NOTICE OF DATE OF BOARD MEETING Regulatory Filings	2025-03-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025 Regulatory Filings	2025-03-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025 Share Issue/Capital Change	2025-02-03	English
HIGHTIDE COMPLETES PATIENT ENROLLMENT IN A HEAD-TO-HEAD PHASE III CLINICAL TRIAL EVALUATING HTD1801 VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS Regulatory Filings	2025-01-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024 Regulatory Filings	2025-01-02	English